Peptide Sciences Shut Down: Best EU Alternatives in 2026

In March 2026, Peptide Sciences — a Henderson, Nevada-based research peptide supplier that had operated since 2013 — permanently closed its operations. The company's website went offline, and no new orders were accepted.

While the company did not issue a detailed public statement, industry analysis points to several converging factors:

• Regulatory pressure: The evolving FDA stance on peptide compounding and bulk drug substances created uncertainty for US-based suppliers, even those operating in the 'research chemical' space.

• Payment processing difficulties: Several US peptide suppliers reported increasing challenges with merchant account services and payment processors throughout 2025, as financial institutions tightened policies around peptide-related businesses.

• Market competition: The entry of larger, venture-backed competitors and the growth of international suppliers (particularly from Europe and Asia) compressed margins for established US players.

• Liability concerns: Growing scrutiny of the 'research use only' designation and its practical application raised potential legal exposure for US suppliers.

Despite being a US-based company, Peptide Sciences served a significant European customer base. Many EU-based researchers relied on them for several reasons:

• Product range: Peptide Sciences offered one of the widest catalogs of research peptides, including less common bioregulators and novel sequences.

• Third-party testing: The company published Certificates of Analysis (COAs) with HPLC purity data and mass spectrometry confirmation for most products.

• Reliability: With over a decade of operation, the brand had built significant trust in the research community.

The shutdown means European buyers must transition to alternative suppliers. However, this transition also presents an opportunity: sourcing from EU-based suppliers can offer advantages including faster shipping, no customs delays, VAT-compliant invoicing, and GDPR-compliant data handling.

When evaluating alternative peptide research suppliers in Europe, prioritize the following criteria:

1. Certificate of Analysis (COA) Every batch should come with a COA showing: • HPLC purity analysis (≥ 98% is the gold standard for research-grade peptides) • Mass spectrometry (MS) confirmation of molecular identity • Endotoxin testing (LAL assay) for injectable-grade preparations • Amino acid analysis where applicable

2. Third-party verification The best suppliers use independent, accredited laboratories for quality testing — not just in-house analysis. Look for ISO 17025-accredited lab reports or named third-party testing facilities.

3. Manufacturing standards EU-based manufacturers should comply with: • GMP (Good Manufacturing Practice) or cGMP standards • ISO 9001 quality management certification • REACH and CLP regulations for chemical substances

4. Shipping and storage Peptides are sensitive to temperature. Reliable suppliers should: • Ship with cold packs or dry ice for temperature-sensitive products • Use insulated packaging • Provide tracking and insurance • Store inventory under appropriate conditions (typically -20°C for lyophilized peptides)

5. Legal compliance Legitimate EU suppliers should: • Have a registered business entity in an EU member state • Provide proper invoicing with VAT numbers • Clearly label products as 'for research use only' or 'for laboratory use' • Not make clinical claims or dosing recommendations for human use

6. Customer support and transparency Look for suppliers that provide: • Accessible customer service (ideally in your language) • Clear return/refund policies • Published sourcing information (where peptides are synthesized) • Active presence in research communities

The closure of Peptide Sciences marks a significant shift in the global peptide research supply landscape. For European buyers, the key takeaways are:

• Diversify suppliers: Relying on a single source — especially one in a different regulatory jurisdiction — creates vulnerability. Consider establishing relationships with multiple EU-based suppliers.

• Prioritize quality verification: Use the COA/testing criteria outlined above to evaluate any new supplier. Price should not be the primary decision factor for research-grade peptides.

• Stay informed on regulation: Both US and EU regulatory environments are evolving. The FDA's recent reclassification of 14 peptides to Category 1 (see our related article) and ongoing EU pharmaceutical legislation reform will continue to shape market access.

• Consider EU advantages: EU-based suppliers offer logistical benefits (faster delivery, no customs), regulatory alignment (VAT compliance, GDPR), and often equivalent or superior product quality.

The peptide research market is adapting, and EU-based suppliers are well-positioned to fill the gap left by Peptide Sciences. Apply rigorous quality criteria, and the transition should be straightforward.